The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved ...
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab RAHWAY, N.J., September 15 ...
Some results have been hidden because they may be inaccessible to you